@entity191 ( @entity191 ) strongly affects quality of life (QoL). Continuous intraduodenal administration of levodopa (IDL) is efficacious, but entails high costs. This study aims to estimate these costs in routine care. 10 @entity1 with advanced- @entity191 who switched from oral medication to IDL were assessed at baseline, and subsequently at 3, 6, 9 and 12  months follow-up. We used the Unified @entity191 Rating Scale (UPDRS) for function and 15D for Quality of Life (QoL). Costs were assessed using quarterly structured @entity1 questionnaires and hospital registries. Costs per quality adjusted life year (QALY) were estimated for conventional treatment prior to switch and for 1-year treatment with IDL. Probabilistic sensitivity analysis was based on bootstrapping. IDL significantly improved functional scores and was safe to use. One-year conventional oral treatment entailed 0.63 QALY while IDL entailed 0.68 (p  >  0.05). The estimated total 1-year treatment cost was NOK419,160 on conventional treatment and NOK890,920 on IDL, representing a cost of NOK9.2 million (< @entity7634 >1.18 mill) per additional QALY. The incremental cost per unit UPDRS improvement was NOK25,000 (< @entity7634 >3,250). Medication was the dominant cost during IDL (45  % of total costs), it represented only 6.4  % of the total for conventional treatment. IDL improves function but is not cost effective using recommended thresholds for cost/QALY in Norway.

Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity7634 :: ('9319', 'Species') :: ['euro'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Advanced-stage Parkinson's disease", 'PD']
@entity1 :: (9606,Species) :: ['patients']
